MIRA Pharmaceuticals (MIRA) Competitors $1.18 -0.07 (-5.24%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.15 -0.02 (-1.79%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. CLYM, CLLS, TCRX, OKYO, UNCY, PLRX, JSPR, ZURA, EPIX, and EXOZShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Climb Bio (CLYM), Cellectis (CLLS), TScan Therapeutics (TCRX), OKYO Pharma (OKYO), Unicycive Therapeutics (UNCY), Pliant Therapeutics (PLRX), Jasper Therapeutics (JSPR), Zura Bio (ZURA), ESSA Pharma (EPIX), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Its Competitors Climb Bio Cellectis TScan Therapeutics OKYO Pharma Unicycive Therapeutics Pliant Therapeutics Jasper Therapeutics Zura Bio ESSA Pharma eXoZymes Climb Bio (NASDAQ:CLYM) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the media prefer CLYM or MIRA? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Climb Bio. MarketBeat recorded 3 mentions for MIRA Pharmaceuticals and 1 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.00 beat MIRA Pharmaceuticals' score of -0.33 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of CLYM or MIRA? 69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 0.8% of Climb Bio shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate CLYM or MIRA? Climb Bio currently has a consensus price target of $9.00, indicating a potential upside of 603.13%. MIRA Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,091.49%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe MIRA Pharmaceuticals is more favorable than Climb Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is CLYM or MIRA more profitable? Climb Bio's return on equity of -43.95% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -43.95% -42.94% MIRA Pharmaceuticals N/A -341.08%-272.93% Which has more volatility & risk, CLYM or MIRA? Climb Bio has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Which has better earnings and valuation, CLYM or MIRA? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$73.90M-$2.38-0.54MIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.30 SummaryMIRA Pharmaceuticals beats Climb Bio on 7 of the 13 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.88M$2.88B$5.50B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-2.3021.5627.6020.30Price / SalesN/A174.49369.54104.24Price / CashN/A41.9536.6357.47Price / Book9.047.518.055.68Net Income-$7.85M-$55.05M$3.18B$249.13M7 Day Performance-5.62%4.61%2.82%3.30%1 Month Performance-16.07%4.89%3.69%5.20%1 Year Performance104.35%5.84%35.41%21.37% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals2.8182 of 5 stars$1.18-5.2%$14.00+1,091.5%+104.3%$19.88MN/A-2.302Gap UpHigh Trading VolumeCLYMClimb Bio2.6836 of 5 stars$1.20-0.8%$9.00+650.0%N/A$81.77MN/A-0.509CLLSCellectis3.0778 of 5 stars$1.44-2.0%$4.00+177.8%-22.7%$81.71M$49.22M-1.67290News CoverageGap DownTCRXTScan Therapeutics2.0114 of 5 stars$1.45+0.7%$7.80+437.9%-74.2%$81.49M$2.82M-1.33100Positive NewsOKYOOKYO Pharma1.9132 of 5 stars$2.19-7.6%$7.00+219.6%+145.8%$80.19MN/A0.007Gap DownUNCYUnicycive Therapeutics3.1844 of 5 stars$7.11+12.1%$60.00+743.9%-5.4%$80.14M$680K-1.399High Trading VolumePLRXPliant Therapeutics4.0105 of 5 stars$1.25-2.3%$13.31+965.0%-88.2%$78.57M$1.58M-0.3590Positive NewsJSPRJasper Therapeutics1.9132 of 5 stars$5.13-0.4%$62.22+1,112.9%-68.3%$77.36MN/A-0.9820Gap UpZURAZura Bio3.3346 of 5 stars$1.12-0.9%$14.33+1,179.8%-67.6%$77.26MN/A-1.603Positive NewsGap UpEPIXESSA Pharma1.3502 of 5 stars$1.72-0.6%$2.00+16.3%-64.1%$76.79MN/A-2.7350News CoverageEXOZeXoZymesN/A$10.50+14.8%N/AN/A$76.57M$70K0.0029News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Climb Bio Competitors Cellectis Competitors TScan Therapeutics Competitors OKYO Pharma Competitors Unicycive Therapeutics Competitors Pliant Therapeutics Competitors Jasper Therapeutics Competitors Zura Bio Competitors ESSA Pharma Competitors eXoZymes Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
